TERNS PHARMACEUTICALS INC. - COMMON STOCK

Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress™ 2022

22 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022

08 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer

01 Jun 2022 15:05:01 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates

16 May 2022 15:05:01 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

04 Apr 2022 15:05:00 By Nasdaq GlobeNewswire

Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201

21 Mar 2022 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

03 Mar 2022 15:05:01 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference

28 Feb 2022 15:05:01 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer

06 Jan 2022 06:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference

03 Jan 2022 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

15 Nov 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting® Digital Experience 2021

12 Nov 2021 06:05:00 By Nasdaq GlobeNewswire

Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR-β agonist TERN-501

09 Nov 2021 15:05:01 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting® Digital Experience 2021

18 Oct 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference

05 Oct 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors

28 Sep 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

08 Sep 2021 06:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

02 Sep 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

16 Aug 2021 15:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

03 Aug 2021 15:05:00 By Nasdaq GlobeNewswire